β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model
Ehud Zigmond,1,* Oshrat Tayer-Shifman,1,* Gadi Lalazar,1 Ami Ben Ya'acov,1 Sarah Weksler-Zangen,2 David Shasha,1 Miriam Sklair-Levy,3 Lidya Zolotarov,1 Zvi Shalev,1 Rony Kalman,2 Ehud Ziv,2 Itamar Raz,2 Yaron Ilan1 1Liver Unit, 2Diabetes Unit, 3Department of Radiology, Hebrew University-Had...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/291cdca6640247d1b8760991bd6ac249 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:291cdca6640247d1b8760991bd6ac249 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:291cdca6640247d1b8760991bd6ac2492021-12-02T04:18:25Zβ-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model1178-7031https://doaj.org/article/291cdca6640247d1b8760991bd6ac2492014-10-01T00:00:00Zhttp://www.dovepress.com/beta-glycosphingolipids-ameliorated-non-alcoholic-steatohepatitis-in-t-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031 Ehud Zigmond,1,* Oshrat Tayer-Shifman,1,* Gadi Lalazar,1 Ami Ben Ya'acov,1 Sarah Weksler-Zangen,2 David Shasha,1 Miriam Sklair-Levy,3 Lidya Zolotarov,1 Zvi Shalev,1 Rony Kalman,2 Ehud Ziv,2 Itamar Raz,2 Yaron Ilan1 1Liver Unit, 2Diabetes Unit, 3Department of Radiology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel *These authors contributed equally to this workAbstract: Liver steatosis is a common characteristic of obesity and type 2 diabetes, and fatty liver disease is increasingly recognized as a major health burden. Accumulating evidence suggests that β-glycosphingolipids play an important role in insulin sensitivity and thus could affect hepatic steatosis. To determine the effect associated with β-glycosphingolipid-mediated amelioration of liver injury, seven groups of Psammomys obesus on a high-energy diet were studied. Animals were treated with daily injections of β-glucosylceramide, β-lactosylceramide, or a combination of both. β-glycosphingolipids ameliorated the hepatic injury manifested by decreased liver enzymes, liver weight, and hepatic fat, and improved liver histology. Administration of both β-glucosylceramide and β-lactosylceramide also decreased interferon (IFN)-γ serum levels. These effects were associated with improved serum cholesterol and triglyceride levels. These data suggest that β-glycosphingolipids ameliorate liver injury in an animal model of nonalcoholic steatohepatitis.Keywords: NAFLD, glycolipids, STAT, NASH, insulin resistance, diabetesZigmond ETayer-Shifman OLalazar GBen Ya'acov AWeksler-Zangen SShasha DSklair-Levy MZolotarov LShalev ZKalman RZiv ERaz IIlan YDove Medical PressarticlePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol 2014, Iss default, Pp 151-158 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Zigmond E Tayer-Shifman O Lalazar G Ben Ya'acov A Weksler-Zangen S Shasha D Sklair-Levy M Zolotarov L Shalev Z Kalman R Ziv E Raz I Ilan Y β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model |
| description |
Ehud Zigmond,1,* Oshrat Tayer-Shifman,1,* Gadi Lalazar,1 Ami Ben Ya'acov,1 Sarah Weksler-Zangen,2 David Shasha,1 Miriam Sklair-Levy,3 Lidya Zolotarov,1 Zvi Shalev,1 Rony Kalman,2 Ehud Ziv,2 Itamar Raz,2 Yaron Ilan1 1Liver Unit, 2Diabetes Unit, 3Department of Radiology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel *These authors contributed equally to this workAbstract: Liver steatosis is a common characteristic of obesity and type 2 diabetes, and fatty liver disease is increasingly recognized as a major health burden. Accumulating evidence suggests that β-glycosphingolipids play an important role in insulin sensitivity and thus could affect hepatic steatosis. To determine the effect associated with β-glycosphingolipid-mediated amelioration of liver injury, seven groups of Psammomys obesus on a high-energy diet were studied. Animals were treated with daily injections of β-glucosylceramide, β-lactosylceramide, or a combination of both. β-glycosphingolipids ameliorated the hepatic injury manifested by decreased liver enzymes, liver weight, and hepatic fat, and improved liver histology. Administration of both β-glucosylceramide and β-lactosylceramide also decreased interferon (IFN)-γ serum levels. These effects were associated with improved serum cholesterol and triglyceride levels. These data suggest that β-glycosphingolipids ameliorate liver injury in an animal model of nonalcoholic steatohepatitis.Keywords: NAFLD, glycolipids, STAT, NASH, insulin resistance, diabetes |
| format |
article |
| author |
Zigmond E Tayer-Shifman O Lalazar G Ben Ya'acov A Weksler-Zangen S Shasha D Sklair-Levy M Zolotarov L Shalev Z Kalman R Ziv E Raz I Ilan Y |
| author_facet |
Zigmond E Tayer-Shifman O Lalazar G Ben Ya'acov A Weksler-Zangen S Shasha D Sklair-Levy M Zolotarov L Shalev Z Kalman R Ziv E Raz I Ilan Y |
| author_sort |
Zigmond E |
| title |
β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model |
| title_short |
β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model |
| title_full |
β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model |
| title_fullStr |
β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model |
| title_full_unstemmed |
β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model |
| title_sort |
β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the psammomys obesus model |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/291cdca6640247d1b8760991bd6ac249 |
| work_keys_str_mv |
AT zigmonde betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT tayershifmano betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT lalazarg betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT benyaacova betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT wekslerzangens betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT shashad betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT sklairlevym betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT zolotarovl betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT shalevz betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT kalmanr betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT zive betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT razi betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel AT ilany betaglycosphingolipidsamelioratednonalcoholicsteatohepatitisinthepsammomysobesusmodel |
| _version_ |
1718401299417923584 |